Boston Scientific CEO Michael Mahoney predicts a long-awaited return to growth for the company in the second half of 2013, driven largely by five new products acquired through acquisitions. And Watchmen may have the biggest expectations behind it of the bunch.
Topera first disclosed its $25 million Series C financing in a regulatory filing in March, but now it's revealing the investors behind the deal, and the lead one is a big fish indeed--New Enterprise Associates.
ARCA Biopharma is planning a Phase IIb/III trial of Gencaro, an investigational atrial fibrillation drug, and Medtronic has signed on to outfit each patient with an implanted CRT-D, measuring the therapy's effect.
After all the handwringing over the results of its Prevail study, Boston Scientific revealed that Watchman proved safer than earlier data suggested, putting to rest rumors that the company was downplaying a failed trial.
North Carolina medical device developer nContact has surpassed the halfway mark in its bid to raise $13 million. The company has reeled in $6.74 million so far.
While Boston Scientific makes headlines with Watchman, St. Jude Medical is working on a stroke-preventing heart device of its own, launching a pivotal trial for the Amplatzer Cardiac Plug.
After stunning analysts with a contrary announcement this week, Boston Scientific is back on track to present the full results of its latest study on Watchman, a stroke-preventing device that could help the company reverse its cardiac fortunes.
Boston Scientific is slated to present late-breaking study data on its much-anticipated Watchman device, but now the company says it will only unveil some of the safety results, spurring analyst speculation that the stroke-prevention tech hasn't lived up to its hype.
Boston Scientific's Watchman atrial fibrillation device improved patient quality of life over drug therapy, according to early results from its pivotal trial.
Atricure enjoyed large revenue gains in both its 2012 fourth quarter and fiscal year, as the company ramped up sales efforts both in the U.S. and abroad for its ablation devices to treat atrial fibrillation. But the company's losses grew for the year, due in part to investments in training and marketing, and pricing pressures.